Over half of the SMARCA4 mutations in human cancer samples are missense mutations that tend to cluster in the catalytic domain, at subunit–subunit interaction interfaces, and at nucleosome binding sites [1, 7]. This evidence concerns the gene SMARCA4 and cancer.